Trial Profile
A study to evaluate the persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria chronically treated with Eculizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2016
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Biomarker; Pharmacodynamics
- 04 Feb 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology